Familial pancreatic cancer

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Familial pancreatic cancer (FPC) includes those kindreds that contain at least two first-degree relatives with pancreatic ductal adenocarcinoma. At least 12 known hereditary syndromes or genes are associated with increased risk of developing pancreatic cancer, the foremost being BRCA2 and CDKN2A. Research into the identification of mutations in known cancer predisposition genes and through next-generation sequencing has revealed extensive heterogeneity. The development of genetic panel testing has enabled genetic risk assessment and predisposition testing to be routinely offered. Precision oncology has opened the possibility of “incidental” germline mutations that may have implications for family members. However, in both cases, evidence-based recommendations for managing patients and at-risk family members in light of genetic status remain emergent, with current practice based on expert opinion.

Original languageEnglish (US)
Pages (from-to)548-553
Number of pages6
JournalSeminars in Oncology
Volume43
Issue number5
DOIs
StatePublished - Oct 1 2016

Fingerprint

Pancreatic Neoplasms
Germ-Line Mutation
Neoplasm Genes
Expert Testimony
Genetic Testing
Adenocarcinoma
Mutation
Research
Genes

Keywords

  • BRCA2
  • CDKN2A
  • Genetic testing
  • Pancreatic cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Familial pancreatic cancer. / Petersen, Gloria M.

In: Seminars in Oncology, Vol. 43, No. 5, 01.10.2016, p. 548-553.

Research output: Contribution to journalReview article

Petersen, Gloria M. / Familial pancreatic cancer. In: Seminars in Oncology. 2016 ; Vol. 43, No. 5. pp. 548-553.
@article{69cb66a4db2d471c922876a3825a9905,
title = "Familial pancreatic cancer",
abstract = "Familial pancreatic cancer (FPC) includes those kindreds that contain at least two first-degree relatives with pancreatic ductal adenocarcinoma. At least 12 known hereditary syndromes or genes are associated with increased risk of developing pancreatic cancer, the foremost being BRCA2 and CDKN2A. Research into the identification of mutations in known cancer predisposition genes and through next-generation sequencing has revealed extensive heterogeneity. The development of genetic panel testing has enabled genetic risk assessment and predisposition testing to be routinely offered. Precision oncology has opened the possibility of “incidental” germline mutations that may have implications for family members. However, in both cases, evidence-based recommendations for managing patients and at-risk family members in light of genetic status remain emergent, with current practice based on expert opinion.",
keywords = "BRCA2, CDKN2A, Genetic testing, Pancreatic cancer",
author = "Petersen, {Gloria M}",
year = "2016",
month = "10",
day = "1",
doi = "10.1053/j.seminoncol.2016.09.002",
language = "English (US)",
volume = "43",
pages = "548--553",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Familial pancreatic cancer

AU - Petersen, Gloria M

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Familial pancreatic cancer (FPC) includes those kindreds that contain at least two first-degree relatives with pancreatic ductal adenocarcinoma. At least 12 known hereditary syndromes or genes are associated with increased risk of developing pancreatic cancer, the foremost being BRCA2 and CDKN2A. Research into the identification of mutations in known cancer predisposition genes and through next-generation sequencing has revealed extensive heterogeneity. The development of genetic panel testing has enabled genetic risk assessment and predisposition testing to be routinely offered. Precision oncology has opened the possibility of “incidental” germline mutations that may have implications for family members. However, in both cases, evidence-based recommendations for managing patients and at-risk family members in light of genetic status remain emergent, with current practice based on expert opinion.

AB - Familial pancreatic cancer (FPC) includes those kindreds that contain at least two first-degree relatives with pancreatic ductal adenocarcinoma. At least 12 known hereditary syndromes or genes are associated with increased risk of developing pancreatic cancer, the foremost being BRCA2 and CDKN2A. Research into the identification of mutations in known cancer predisposition genes and through next-generation sequencing has revealed extensive heterogeneity. The development of genetic panel testing has enabled genetic risk assessment and predisposition testing to be routinely offered. Precision oncology has opened the possibility of “incidental” germline mutations that may have implications for family members. However, in both cases, evidence-based recommendations for managing patients and at-risk family members in light of genetic status remain emergent, with current practice based on expert opinion.

KW - BRCA2

KW - CDKN2A

KW - Genetic testing

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84994021821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994021821&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2016.09.002

DO - 10.1053/j.seminoncol.2016.09.002

M3 - Review article

C2 - 27899186

AN - SCOPUS:84994021821

VL - 43

SP - 548

EP - 553

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5

ER -